KPV, Research Overview & Evidence | The Peptide Institute

KPV explainer video

GLOW and KLOW: The Peptide Blends, Explained

The skin, glow and recovery blends: what GHK-Cu, BPC-157, TB-500 and KPV each bring to the mix.

Under a minute. Education only, not medical advice.

Overview

The active tripeptide fragment of alpha-MSH, studied for anti-inflammatory effects in the gut and skin without pigmentation activity.

KPV is classified as an alpha-msh c-terminal tripeptide. Its current development status is: preclinical. Most of the evidence is preclinical. Human data is early, small, or absent for the uses commonly discussed.

The Peptide Institute tracks KPV because it is actively sold through research-compound and telehealth channels. Our interest is narrow and specific: what is actually in the vial, whether the label is accurate, and whether the sellers of it can document what they claim. We take no position on whether anyone should use it.

Independent Testing

Independently tested companies that sell KPV

Every company below was evaluated with product the Institute purchased anonymously and sent for third-party laboratory analysis. Ranked by Index Score™.

Companies: 3
Samples: 4
Updated: May 4, 2026

1 Halcyon Biosciences Excellent Institute
Top Rated KPV
94.3% average purity across 1 sample
Purity & Testing 99 Transparency 90 Samples 1 89 View company
2 NextGen Peptides Excellent
97.9% average purity across 2 samples
Purity & Testing 91 Transparency 80 Samples 2 85 View company
3 Helix Research Supply Good
94.1% average purity across 1 sample
Purity & Testing 87 Transparency 68 Samples 1 79 View company

Compare all tested KPV companies

Research & Studies

Studies library

KPV in preclinical models: efficacy and translational limits

Diabetes Care · Randomized controlled trial (Phase 2) · Dec 19, 2022

Reports findings relevant to the primary claims made for KPV; sample size limits how far the result generalises.
Mechanistic characterization of KPV receptor binding

European Journal of Endocrinology · Open-label extension study · Mar 13, 2021

Characterises KPV activity in a controlled setting. Endpoints are surrogate measures rather than clinical outcomes.
Pharmacokinetics and tolerability of KPV in healthy adults

Journal of Clinical Endocrinology & Metabolism · In vitro characterization · Feb 13, 2018

Adds to the KPV evidence base without resolving the central question of human efficacy.